Speaker illustration

Doctor Antonio Abbate

University of Virginia, Charlottesville (United States of America)

Member of:

European Society of Cardiology
Heart Failure Association

Dr. Abbate received his Medical Degree from the University Campus Bio-Medico, and Cardiovascular Medicine training at the Catholic University of the Sacred Heart, Rome, Italy, and also earned a PhD in Molecular and Cellular Cardiology. He then moved to Richmond, Virginia, USA, and completed a Residency in Internal Medicine at the Virginia Commonwealth University and joined the faculty rising to the rank of Professor with tenure. In 2022, Dr. Abbate relocated to the University of Virginia in Charlottesville, VA, as the Ruth C. Heede Professor of Cardiology in the Berne Cardiovascular Research Center and Heart and Vascular Center. Dr. Abbate is board certified in Internal Medicine and Cardiovascular Medicine and Fellow of the American College of Cardiology, Fellow of American Heart Association, and Fellow of the European Society of Cardiology. Dr Abbate’s research focuses on cardio-immunology Dr. Abbate attends the coronary intensive care unit, general cardiology and cardio-oncology.

Diabetes mellitus and response to IL-1 blockade with Anakinra after ST-elevation myocardial infarction: a pooled analysis of the VCU-ART studies

Event: ESC Congress 2023

Topic: Inflammation and Immunity

Session: Diabetes and stable coronary artery disease


Interleukin -1 inhibitors.

Event: Heart Failure 2020

Topic: Basic Science

Session: Lessons from recent and ongoing heart failure trials


Interleukin-1 blockade with Anakinra in ST-segment elevation acute myocardial infarction: Results from the VCUART3 study

Event: ESC Congress 2019

Topic: Pharmacotherapy

Session: Emerging treatments in acute coronary syndromes


Effects of Interleukin-1 blockade with Anakinra on cardiac function in ST-segment elevation acute myocardial infarction: results from the VCUART3 echocardiography study

Event: ESC Congress 2019

Topic: ST-Elevation Myocardial Infarction (STEMI)

Session: New insights for acute coronary syndrome pharmacotherapy


ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb